Page URL: https://www.bionews.org.uk/page_90528

Scientists uncover the genetics of lung cancer

12 November 2007
Appeared in BioNews 433

A large-scale American study has pinpointed a number of new regions within the genome associated with the development of lung cancer: the world's biggest cancer killer. Researchers hope their findings will lead to new and improved treatments.

The $1million multi-centre study, published online in Nature, screened the genome looking at SNPs (single nucleotide polymorphisms) - single letter 'variants' -looking for correspondence between more than 500 tumour specimens.

'This view of the lung cancer genome is unprecedented, both in its breadth and depth,' said Matthew Meyerson, of the Broad Institute in Cambridge, Massachusetts, who led the study. 'It lays an essential foundation, and has already pinpointed an important gene that controls the growth of lung cells. This information offers crucial inroads to the biology of lung cancer and will help shape new strategies for cancer diagnosis and therapy.' 50 unique regions were identified, with more than two-thirds in areas not previously implicated in lung cancer. The identification of one gene in particular is causing excitement amongst researchers. The NKX2.1 gene - apparently duplicated many times in lung cancer - operates normally as a 'master regulator' - controlling the activity of other key genes in cells called alveoli- hollow cavities in the lungs that are the primary site of oxygen absorption. Despite only being expressed in the alveoli, NKX2.1 appears to promote cancer growth making it a ripe target for future treatments.

There are around 40,000 cases of lung cancer diagnosed in the UK each year, and around 33,500 deaths, giving it the lowest survival rates of any cancer: only seven per cent of patients are alive after five years. Although 90 percent of lung cancer is induced by genetic damage from smoking, genetic predisposition to the disorder is known to be important in the development of the disease.

The SNP screen is a prequel to a much larger $8million study employing gene sequencing, which has a much higher resolution, to identify more subtle genetic changes in lung cancer. 'You ain't seen nothin' yet,' said Meyerson.

SOURCES & REFERENCES
Characterizing the cancer genome in lung adenocarcinoma
Nature |  4 November 2007
Lung cancer ravages revealed
The Daily Telegraph |  5 November 2007
Researchers detail cancer DNA damage
The Boston Globe |  5 November 2007
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
9 November 2009 - by Ailsa Stevens 
A UK company has launched a genetic test aimed at predicting the risk of smokers developing lung cancer. The test, known as Respirigene, assesses 20 different genetic markers which have previously been linked to lung cancer in combination with other known risk factors for the disease, such as age, any prior medical history of chronic lung disease, and family history of lung cancer, to decide whether an individual is in a high, moderate or low risk category for lung cancer....
7 April 2008 - by Dr Charlotte Maden 
Scientists have found evidence that there is a strong genetic link to lung cancer. The findings, from three teams in Iceland, France and the US, will help understanding of the genetic basis of the disease and the role tobacco plays in its development. Lung cancer is the...
19 December 2005 - by BioNews 
The US government has announced that it will provide initial funds of $100 million for the 'Cancer Genome Atlas', a project that aims to catalogue the hundreds of different genetic errors that can turn a normal cell into a cancerous one. Launched by the National Institutes of Health (NIH) last...
4 May 2004 - by BioNews 
Targeted cancer treatments, based on genetic profiling results, could soon become a reality. A team lead by researchers at the Dana-Farber Cancer Institute, in the US, has found that only lung tumours with a particular gene mutation are likely to respond to treatment with the drug gefitinib. The work is...
25 October 1999 - by BioNews 
The Wellcome Trust is to fund a £10m Cancer Genome Project to detect genes that are mutated in human cancers and release that information to a public database. The project will be based at the Sanger Centre near Cambridge which forms a part of the international Human Genome Project - a...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.